As 2025 draws to a close, biomedical and materials science frontiers ignite with transformative potential: the U.S. government's ambitious push...
Read moreThe FDA's May 16, 2025, clearance of Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio—the first blood test aiding Alzheimer's diagnosis—revolutionizes access...
Read moreOzempic's semaglutide has affirmed profound heart protections in 2025's landmark studies, slashing major adverse cardiovascular events (MACE)—heart attacks, strokes, deaths—by...
Read moreAcute myeloid leukemia (AML) relapse stems from cunning cellular adaptations that shield malignant blasts from chemotherapy's assault. Recent investigations illuminate...
Read moreGlioblastoma multiforme (GBM), the most lethal primary brain cancer, claims lives rapidly due to its invasiveness and treatment barriers like...
Read moreIn a move sparking widespread controversy, the Environmental Protection Agency (EPA) has greenlit multiple pesticide products incorporating per- and polyfluoroalkyl...
Read moreThe 2025-2026 influenza season is off to a concerning start, with early indicators pointing to heightened severity across the United...
Read moreIn a tragic milestone, a Washington state resident has become the world’s first confirmed human death from the highly pathogenic...
Read moreThe EPA ignited outrage on November 20, 2025, approving isocycloseram—a PFAS "forever chemical"—in ten pesticide products for crops like oranges,...
Read moreIn a groundbreaking leap for oncology, researchers at Washington University School of Medicine in St. Louis and Northwestern University unveiled...
Read more